Stock listing
Frankfurt:8F8 SynAct Pharma AB Aktie
German listing (Frankfurt) of SynAct Pharma AB · home listing Stockholm:SYNACT
Follow SynAct Pharma AB into a list and get an email when it puts out news.
Share price · FWB:8F8
€1.14 EUR -0.01 (-0.5%)
Close on Nov 20, 2026
- Day range
- €1.14 – €1.16 EURNov 20, 2026
- Market cap
- €63.73M EURAt the close on Nov 20, 2026 · price × 56.00M shares outstanding
- 52-week range
- €0.97 – €2.24 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:SYNACT · Home | 13.00 SEK | 0.00 (0.0%) | 127,189 | 13.00 | 13.16 | 12.62 | 13.00 | Close on Nov 20, 2026 |
| Frankfurt:8F8 | €1.138 EUR | -0.006 (-0.5%) | — | €1.142 | €1.158 | €1.138 | €1.144 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:8F8 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.334 | -0.057 | -4.1% | €1.348 | €1.356 | €1.33 | 0 | |
| €1.391 | -0.021 | -1.5% | €1.425 | €1.425 | €1.374 | 0 | |
| €1.412 | -0.014 | -1.0% | €1.411 | €1.412 | €1.409 | 0 | |
| €1.426 | -0.006 | -0.4% | €1.467 | €1.475 | €1.423 | 0 | |
| €1.432 | -0.01 | -0.7% | €1.434 | €1.434 | €1.432 | 0 | |
| €1.442 | -0.10 | -6.5% | €1.491 | €1.495 | €1.436 | 0 | |
| €1.542 | -0.066 | -4.1% | €1.573 | €1.573 | €1.54 | 0 | |
| €1.608 | -0.051 | -3.1% | €1.627 | €1.641 | €1.598 | 0 | |
| €1.659 | +0.089 | +5.7% | €1.612 | €1.659 | €1.605 | 0 | |
| €1.57 | +0.036 | +2.3% | €1.539 | €1.579 | €1.517 | 0 | |
| €1.534 | -0.013 | -0.8% | €1.544 | €1.548 | €1.517 | 0 | |
| €1.547 | -0.008 | -0.5% | €1.541 | €1.554 | €1.538 | 0 | |
| €1.555 | +0.026 | +1.7% | €1.553 | €1.555 | €1.549 | 0 | |
| €1.529 | +0.01 | +0.7% | €1.517 | €1.532 | €1.517 | 0 | |
| €1.519 | +0.006 | +0.4% | €1.523 | €1.523 | €1.512 | 0 | |
| €1.513 | +0.013 | +0.9% | €1.522 | €1.533 | €1.513 | 0 | |
| €1.50 | -0.019 | -1.3% | €1.496 | €1.509 | €1.495 | 0 | |
| €1.519 | -0.003 | -0.2% | €1.524 | €1.531 | €1.515 | 0 | |
| €1.522 | +0.013 | +0.9% | €1.53 | €1.533 | €1.522 | 0 | |
| €1.509 | +0.01 | +0.7% | €1.515 | €1.516 | €1.509 | 0 | |
| €1.499 | -0.022 | -1.4% | €1.501 | €1.507 | €1.496 | 0 | |
| €1.521 | +0.014 | +0.9% | €1.53 | €1.531 | €1.518 | 0 | |
| €1.507 | -0.034 | -2.2% | €1.504 | €1.514 | €1.502 | 0 | |
| €1.541 | +0.021 | +1.4% | €1.545 | €1.545 | €1.524 | 0 | |
| €1.52 | +0.014 | +0.9% | €1.523 | €1.524 | €1.506 | 0 | |
| €1.506 | +0.017 | +1.1% | €1.495 | €1.519 | €1.488 | 0 | |
| €1.489 | -0.057 | -3.7% | €1.525 | €1.527 | €1.478 | 0 | |
| €1.546 | 0.00 | 0.0% | €1.555 | €1.567 | €1.537 | 0 | |
| €1.546 | +0.013 | +0.8% | €1.546 | €1.546 | €1.546 | 0 | |
| €1.533 | -0.005 | -0.3% | €1.537 | €1.539 | €1.531 | 0 | |
| €1.538 | -0.032 | -2.0% | €1.543 | €1.543 | €1.532 | 0 | |
| €1.57 | +0.009 | +0.6% | €1.572 | €1.574 | €1.565 | 0 | |
| €1.561 | -0.008 | -0.5% | €1.558 | €1.561 | €1.552 | 0 | |
| €1.569 | +0.009 | +0.6% | €1.556 | €1.588 | €1.551 | 0 | |
| €1.56 | -0.026 | -1.6% | €1.545 | €1.569 | €1.536 | 0 | |
| €1.586 | -0.011 | -0.7% | €1.587 | €1.599 | €1.572 | 0 | |
| €1.597 | +0.016 | +1.0% | €1.603 | €1.603 | €1.591 | 0 | |
| €1.581 | -0.033 | -2.0% | €1.583 | €1.595 | €1.579 | 0 | |
| €1.614 | -0.018 | -1.1% | €1.61 | €1.617 | €1.597 | 0 | |
| €1.632 | -0.034 | -2.0% | €1.646 | €1.65 | €1.629 | 0 | |
| €1.666 | -0.033 | -1.9% | €1.668 | €1.686 | €1.664 | 0 | |
| €1.699 | -0.015 | -0.9% | €1.721 | €1.722 | €1.692 | 0 | |
| €1.714 | -0.021 | -1.2% | €1.721 | €1.746 | €1.713 | 0 | |
| €1.735 | -0.029 | -1.6% | €1.745 | €1.751 | €1.734 | 0 | |
| €1.764 | +0.235 | +15.4% | €1.574 | €1.765 | €1.558 | 0 | |
| €1.529 | -0.125 | -7.6% | €1.575 | €1.576 | €1.521 | 0 | |
| €1.654 | -0.137 | -7.6% | €1.658 | €1.662 | €1.654 | 0 | |
| €1.791 | +0.021 | +1.2% | €1.815 | €1.844 | €1.777 | 0 | |
| €1.77 | -0.001 | -0.1% | €1.771 | €1.773 | €1.77 | 0 | |
| €1.771 | +0.015 | +0.9% | €1.783 | €1.793 | €1.77 | 0 | |
| €1.756 | +0.011 | +0.6% | €1.748 | €1.772 | €1.74 | 0 | |
| €1.745 | +0.02 | +1.2% | €1.751 | €1.753 | €1.735 | 0 | |
| €1.725 | -0.014 | -0.8% | €1.739 | €1.752 | €1.717 | 0 | |
| €1.739 | +0.038 | +2.2% | €1.732 | €1.773 | €1.713 | 0 | |
| €1.701 | -0.035 | -2.0% | €1.789 | €1.802 | €1.701 | 0 | |
| €1.736 | -0.02 | -1.1% | €1.739 | €1.744 | €1.736 | 0 | |
| €1.756 | -0.205 | -10.5% | €1.814 | €1.837 | €1.755 | 0 |
- Ticker
- Frankfurt:8F8
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 18, 2026
Nomination Committee appointed ahead of SynAct Pharma AB AGM 2027
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 26 slides
Latest news
SynAct Pharma to Participate in Investor and Partnering Conferences
Sep 22, 2026
Closed €1.57 (+0.6%) on Sep 22, 2026
WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development
Sep 16, 2026
Closed €1.58 (-2.0%) on Sep 16, 2026
Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026
Sep 7, 2026
Closed €1.76 (+15.4%) on Sep 7, 2026
SynAct Pharma's CEO and CSO Sell Shares
Sep 3, 2026
Closed €1.65 (-7.6%) on Sep 3, 2026
SynAct Pharma publishes Q2 2026 interim results
Aug 20, 2026
Closed €1.76 (-10.5%) on Aug 20, 2026
SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation
Aug 5, 2026
Closed €1.73 (+3.6%) on Aug 5, 2026
SynAct Pharma AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 24 in all · newest Nov 18, 2026 · oldest 2026
- Decks
- 25 decks · latest September 2026
Where SynAct Pharma AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:SYNACT · Home listing | Stockholm | Sweden | SEK |
| Aquis:SYNACS | Aquis | United Kingdom | SEK |
| LS Exchange:A2ALUN | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2ALUN | Lang & Schwarz | Germany | EUR |
| Frankfurt:8F8 · This page | Frankfurt | Germany | EUR |
| gettex:8F8 | gettex | Germany | EUR |
| Aquis:SYNACS | Aquis | United Kingdom | SEK |
| Munich:8F8 | Munich | Germany | EUR |
| Stuttgart:8F8 | Stuttgart | Germany | EUR |
| Tradegate:8F8 | Tradegate | Germany | EUR |
Valuation
Price/book 5.1× against a median of 2.2×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 731.1M SEK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| SynAct Pharma AB · OMXSTO:SYNACT | US$71.29M | US$71.60M | n/a | n/a | n/a | 5.1× | n/a | 0.3× | n/a |
| Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427 | US$73.92M | US$52.72M | n/a | 1,442× | n/a | 3.2× | n/a | 0.0× | n/a |
| Pentixapharm Holding AG · XETR:PTP | US$73.87M | US$69.92M | n/a | 1,158× | n/a | 2.4× | n/a | 0.0× | n/a |
| Dimerix Limited · ASX:DXB | US$73.52M | US$62.98M | n/a | 21.9× | n/a | n/a | −685.3% | n/a | n/a |
| Faron Pharmaceuticals Oy · LSE:FARN | US$72.99M | US$57.36M | n/a | n/a | n/a | 5.7× | n/a | 1.5× | n/a |
| Cellectis S.A. · EURONEXT:ALCLS | US$72.64M | −US$9.64M | n/a | −0.2× | n/a | 1.8× | −115.4% | 2.1× | n/a |
| Kanaph Therapeutics Inc. · KRX:0082N0 | US$72.37M | US$38.83M | n/a | 9.3× | n/a | 2.1× | −729.8% | 0.0× | n/a |
| Eastwood Bio-Medical Canada Inc · TSXV:EBM | US$72.05M | US$72.05M | n/a | 127× | n/a | n/a | −28.5% | n/a | 0.56 |
| Bioton S.A. · GPW:BIO | US$70.64M | US$86.90M | n/a | 1.4× | 6.5× | 0.5× | −3.3% | 0.1× | n/a |
| Coya Therapeutics, Inc. · NASDAQ:COYA | US$69.20M | US$33.40M | n/a | 7.1× | n/a | 2.1× | −643.5% | 0.0× | 1.64 |
| MAIA Biotechnology, Inc. · AMEX:MAIA | US$68.54M | US$68.54M | n/a | n/a | n/a | 4.7× | n/a | 0.0× | 1.62 |
| Median of the others | US$72.50M | US$60.17M | 15.6× | 6.5× | 2.2× | −379.4% | 0.0× | 1.62 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 39.40 SEK · Analysts' mean
- EPS, year to Dec 2026
- -1.68 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Jeppe Øvlesen | Chief Executive Officer |
| Ann Kristin Led | Chief Financial Officer |
| Thomas Boesen | Chief Operating Officer |
| Mads Bjerregaard | Chief Business Officer |
| Thomas Jonassen | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Anders Kronborg | Chairman of the Board |
| Jeppe Ragnar Andersen | Board Member |
| Sten Scheibye | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 | −1.6% |
| Q2 2026 | Aug 20, 2026 | −7.5% |
| Q1 2026 | May 28, 2026 | +9.3% |
| Q4 2025 | Feb 19, 2026 | +3.5% |
| Q3 2025 | Oct 30, 2025 | +13.6% |
| Q2 2025 | Aug 20, 2025 | −1.5% |
| Q1 2025 | May 27, 2025 · Before open | −18.6% |
| Q4 2024 | Feb 18, 2025 · Before open | +3.6% |
| Q3 2024 | Oct 30, 2024 | −1.5% |
| Q2 2024 | Aug 20, 2024 | −10.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 24, 2024 · Before open | −3.4% |
| Q4 2023 | Feb 23, 2024 · Before open | −6.1% |
| Q3 2023 | Oct 24, 2023 · Before open | −2.3% |
| Q2 2023 | Aug 4, 2023 · Before open | +5.3% |
| Q1 2023 | May 5, 2023 · Before open | +0.4% |
| Q4 2022 | Feb 17, 2023 · Before open | 0.0% |
| Q3 2022 | Nov 4, 2022 · Before open | −8.3% |
| Q2 2022 | Aug 5, 2022 · Before open | −3.0% |
| Q1 2022 | May 30, 2022 · Before open | |
| Q4 2021 | Feb 11, 2022 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 26 slides | September 2026 |
| Investor Presentation (April 2026) | Investor deck | 28 slides | April 2026 |
| Investor Presentation (February 2026) | Investor deck | 27 slides | February 2026 |
| Investor Presentation (2025) | Investor deck | 18 slides | 2025 |
| Redeye Theme: Autoimmune and inflammatory disease (October 2023) | Conference | 13 slides | Oct 3, 2023 |
| Corporate Update (September 2023) | Corporate update | 11 slides | Sep 13, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 19 slides | Aug 4, 2023 |
| BIO Boston June 2023 | Conference | 18 slides | June 2023 |
| Investor Presentation (March 2023) | Investor deck | 45 slides | March 2023 |
| Investor Presentation (August 2022) | Investor deck | 37 slides | August 2022 |
All 25 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ABG (May 2022) | Conference | 46 slides | May 19, 2022 |
| Investor Presentation (March 2022) | Investor deck | 36 slides | March 2022 |
| Investor Presentation (February 2022) | Investor deck | 36 slides | February 2022 |
| Investor Presentation (December 2021) | Investor deck | 37 slides | Dec 7, 2021 |
| Investor Presentation (December 2021) | Investor deck | 18 slides | Dec 2, 2021 |
| Kempen Life Sciences Conference 2021 | Conference | 30 slides | May 2021 |
| Investor Presentation (February 2021) | Investor deck | 37 slides | February 2021 |
| Investor Presentation (October 2020) | Investor deck | 27 slides | October 2020 |
| Investor Presentation (May 2018) | Investor deck | 15 slides | May 3, 2018 |
| Sedermeradagen Malmö 2018 | Conference | 17 slides | May 2018 |
| Sedermera Dagen, Copenhagen 2018 | Conference | 15 slides | Mar 13, 2018 |
| Investor Presentation (March 2017) | Investor deck | 17 slides | March 2017 |
| Investor Presentation (November 2016) | Investor deck | 19 slides | November 2016 |
| IPO Roadshow (May 2016) | IPO roadshow | 22 slides | May 2016 |
| Investor Presentation (March 2016) | Investor deck | 19 slides | March 2016 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertibles of series 2026/2027:2 Closed: SEK 100M raised Buyers: Fenja Capital II A/S (second tranche of SEK 50 million) Use of proceeds: Strengthen financial position and support continued clinical development activities and strategic priorities | Nov 18, 2026 | |
| Private placement of new shares Closed: SEK 51.91M raised · SEK 18 a share · Navia Corporate Finance AB Dealers: Navia Corporate Finance AB (lead) Buyers: Hunter Capital (major shareholder that has expressed interest in participating); Johannes Schildt (major shareholder who has expressed interest in participating) Use of proceeds: Increased financial flexibility and extending the cash runway to support post-data partnering discussions | Mar 2, 2026 | US$5.67M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 617.0K | 778.0K | 1.06M | 88.0K | 338.5K | 303.6K | 252.0K | 190.4K | ||
| Gross profit | 0 | 0 | 0 | 0 | 0 | -338.5K | -303.6K | -252.0K | -190.4K | |
| Research and development | 85.6M | 49.3M | 105.1M | 70.1M | 60.5M | 22.8M | 15.2K | 21.8M | ||
| Selling, general and administrative | 31.5M | 40.5M | 33.9M | 35.6M | 16.2M | 8.81M | 24.2M | 28.1M | 17.9M | |
| Operating income | -116.5M | -90.0M | -224.5M | -105.7M | -76.7M | -31.3M | -24.8M | -28.4M | -18.2M | -17.0M |
| Depreciation and amortization | 628.0K | 614.0K | 75.3M | 1.02M | 88.0K | 381.1K | 338.5K | 303.6K | 252.0K | 190.4K |
| EBITDA | -115.9M | -89.4M | -149.2M | -104.7M | -76.6M | -30.9M | -24.5M | -28.1M | -17.9M | -16.8M |
| Interest expense | 3.87M | 2.96M | 830.0K | 1.42M | 110.0K | 39.0K | 2.39M | 146.7K | 155.4K | |
| Income before tax | -119.0M | -90.8M | -224.3M | -107.1M | -76.8M | -31.3M | -27.1M | -28.2M | -18.0M | -17.0M |
| Income tax | -8.16M | -8.42M | -8.47M | -7.86M | -7.50M | -4.75M | -3.15M | -4.80M | -2.64M | -1.54M |
| Net income | -110.8M | -82.4M | -215.8M | -99.2M | -69.3M | -26.6M | -24.0M | -23.4M | -15.4M | -15.5M |
| Earnings per share, basic | -2.17 | -2.08 | -6.64 | -3.60 | -2.68 | -1.23 | -1.62 | -1.70 | -1.24 | -1.30 |
| Earnings per share, diluted | -2.17 | -2.08 | -6.64 | -3.60 | -2.68 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 53.4M | 61.2M | 62.4M | 108.2M | 24.0M | 14.5M | 3.56M | 7.12M | 10.2M | 26.6M |
| Short-term investments | 93.0K | 180.0K | -208.0K | |||||||
| Receivables | 13.4M | 5.96M | 12.4M | 14.7M | 10.7M | 6.46M | 4.90M | 6.02M | 3.87M | 2.92M |
| Inventory | -12.4M | 246.0K | 321.0K | -22.2K | -6.02M | -3.87M | -2.92M | |||
| Current assets | 71.3M | 94.0M | 75.1M | 140.2M | 34.9M | 21.3M | 8.45M | 13.1M | 14.1M | 29.5M |
| Property, plant and equipment | 2.10M | 3.18M | ||||||||
| Goodwill | 0 | 0 | 0 | 0 | ||||||
| Total assets | 220.5M | 270.5M | 228.0M | 142.6M | 38.4M | 21.6M | 23.8M | 14.0M | 15.2M | 30.6M |
| Accounts payable | 9.49M | 17.3M | 9.67M | 4.72M | 4.25M | 2.77M | 5.46M | 3.23M | 1.78M | 3.16M |
| Current liabilities | 21.5M | 28.5M | 24.9M | 15.0M | 15.4M | 5.72M | 10.3M | 3.72M | 2.31M | 3.49M |
| Total debt | 1.81M | 1.88M | 637.0K | 2.06M | 3.09M | |||||
| Total liabilities | 50.2M | 56.4M | 51.8M | 16.1M | 17.5M | 5.72M | 10.3M | 3.72M | 2.31M | 3.49M |
| Shareholders' equity | 170.3M | 214.2M | 176.2M | 126.5M | 20.9M | 15.9M | 13.5M | 10.3M | 12.9M | 27.1M |
| Shares outstanding | 51.1M | 39.5M | 32.5M | 27.6M | 26.0M | 21.7M | 14.8M | 13.8M | 12.4M | 11.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -97.3M | -89.2M | -100.2M | -117.6M | -65.0M | -33.2M | -16.1M | -24.2M | -17.2M | -14.7M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -33.2M | -499.0K | 0 | -264.5K | -903.0K |
| Free cash flow | -97.3M | -89.2M | -100.2M | -117.6M | -65.0M | -33.2M | -16.6M | -24.2M | -17.5M | -15.6M |
| Cash from investing | 0 | 0 | 370.0K | 27.0K | -6.00K | -93.0K | -499.0K | -93.0K | -264.5K | -996.1K |
| Cash from financing | 90.5M | 87.4M | 54.0M | 200.7M | 74.3M | 44.7M | 13.0M | 20.8M | 950.9K | 42.1M |
| Change in cash | -6.87M | -1.79M | -45.8M | 83.2M | 9.32M | 11.0M | -3.56M | -3.09M | -16.4M | 25.8M |
Cap table
Built by 6ix from SynAct Pharma AB’s releases · as of Nov 18, 2026
- Common shares
- 55,998,270
- Fully diluted
- 55,998,270
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 55,998,270 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 55,998,270 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anders Kronborg | Chairman of the Board · Since at least May 7, 2026 |
| Ann Kristin Led | Chief Financial Officer · Since Feb 24, 2026 |
| Jeppe Øvlesen | Chief Executive Officer · Since at least Sep 22, 2026 |
| Jeppe Ragnar Andersen | Board Member · Since at least May 7, 2026 |
| Mads Bjerregaard | Chief Business Officer · Since at least Sep 22, 2026 |
| Sten Scheibye | Board Member · Since at least May 7, 2026 |
| Sten Sörensen | Director · Until Nov 16, 2026 · Past |
| Thomas Boesen | Chief Operating Officer · Since at least Aug 5, 2026 |
| Thomas Jonassen | Chief Scientific Officer · Since at least Sep 16, 2026 |
Log in to ask 6ix AI your own questions about SynAct Pharma AB.